
AARD Stock Forecast & Price Target
AARD Analyst Ratings
Bulls say
Aardvark Therapeutics is supported by exploratory data that suggest ARD-101 produces a real pharmacologic effect in Prader-Willi syndrome, with a modest HQ-CT reduction versus placebo by week two and a 6-point average reduction in the open-label extension among participants switching from placebo. The fact that scores returned near baseline after discontinuation, while placebo showed less rebound, strengthens the interpretation that the observed changes were drug-related rather than random variation, even though the HERO trial was terminated early after randomizing 67 of 90 planned participants. Its favorable tolerability profile, with most adverse events mild to moderate, further supports the case that a gut-restricted oral TAS2R agonist could advance as a differentiated metabolic therapy.
Bears say
Aardvark Therapeutics is a clinical-stage company with no approved products, so its valuation depends heavily on ARD-101 advancing through a still-uncertain regulatory path after the FDA clinical hold and the termination of the HERO and OLE trials. Although the hold was lifted and no cardiac events were seen in the recent ECG study at 200mg and 400mg BID, the company still faces unresolved questions around Phase 3 design, safety interpretation, and whether the initial efficacy signals in PWS are strong enough to support meaningful commercialization. The outlook is further weakened by financing overhang and the risk that ARD-101 may not achieve the market penetration previously hoped for across PWS, hypothalamic obesity, and obesity.
This aggregate rating is based on analysts' research of Aardvark Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
AARD Analyst Forecast & Price Prediction
Start investing in AARD
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Aardvark Therapeutics Inc (AARD) Forecast
AARD Analyst Forecast & Price Prediction
Start investing in AARD
Order type
Buy in
Order amount
Est. shares
0 shares